Acumen Pharmaceuticals, Inc. (ABOS)
NASDAQ: ABOS · Real-Time Price · USD
2.425
+0.045 (1.89%)
Oct 29, 2026, 12:27 PM EDT - Market open
Acumen Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 6 analysts polled by S&P Global, Acumen Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $7.60. The average 1-year stock price forecast is 213.40% higher than the current stock price, while the lowest is $5.00 (+106.19%) and the highest is $10 (+312.37%).
Price Target: $7.60 (+213.40%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Acumen Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Bank of America Securities | Bank of America Securities | Buy Maintains $8 | Buy | Maintains | $8 | +229.90% | Oct 26, 2026 |
| Citi | Citi | Buy Maintains $5 | Buy | Maintains | $5 | +106.19% | Oct 15, 2026 |
| BTIG | BTIG | Buy Maintains $8 | Buy | Maintains | $8 | +229.90% | Sep 17, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.50
from -2.00
EPS Next Year
-1.51
from -1.50
EPS and Forward PE are based on non-GAAP adjusted numbers.